Thymosin Alpha-1 10mg

Thymosin Alpha-1 (Tα1) is a synthetic, acetylated 28-residue peptide identical in sequence to the naturally occurring fragment released from the N-terminus of prothymosin alpha, a 113-amino-acid precursor. In the body the fragment is generated by proteolytic cleavage of prothymosin alpha, and it circulates as one of the best-characterised members of the thymic peptide family. It was among the first thymic peptides to be sequenced and chemically synthesised, and it has one of the largest research and clinical literatures of any immunomodulatory peptide.

In the research-supply context, Thymosin Alpha-1 is studied as a tool compound for investigating immune regulation. Its documented activities in preclinical and clinical models centre on the maturation and differentiation of T lymphocytes, the functional maturation of dendritic cells, and the upregulation of T-helper-1 (Th1) cytokines. It is marketed as an approved pharmaceutical in a number of countries under the brand name Zadaxin for specific infectious-disease indications; the research-grade material supplied here is a distinct matter from that approved product and is provided strictly for laboratory benchwork.

Thymosin Alpha-1 acts as a broad immune modulator rather than through a single receptor. The mechanism most consistently reported in the literature involves signalling through Toll-like receptors, particularly TLR2 and TLR9, on dendritic cells and monocytes, which drives dendritic-cell maturation and activation of downstream MyD88-dependent pathways. Through this route the peptide has been reported to promote the differentiation of immature T cells into functional subsets and to shift cytokine output toward a Th1 profile.

Across preclinical models the peptide is associated with increased production of interleukin-2 and interferon-gamma, enhanced expression of the high-affinity IL-2 receptor on T cells, augmented natural-killer-cell cytotoxicity, and restoration of immune parameters that are suppressed in immunocompromised states. It has also been studied for effects on regulatory T-cell balance and on the resolution phase of inflammation. Because the mechanism spans several arms of the immune response, the literature frames Thymosin Alpha-1 as an immune-reconstituting or immune-normalising agent rather than a simple immunostimulant.

The research literature on Thymosin Alpha-1 spans preclinical immunology and a substantial clinical database. Documented areas of investigation include: T-cell maturation and differentiation; dendritic-cell function and antigen presentation; natural-killer-cell activity; cytokine regulation, particularly Th1 cytokines; immune reconstitution in models of immunodeficiency; use as a vaccine adjuvant to augment antibody and cell-mediated responses; and adjunct roles in models of chronic viral infection and sepsis.

These are descriptions of the published research landscape and are provided for scientific context only. They are not claims of efficacy, and nothing here constitutes medical, clinical, or therapeutic guidance. Ronin Peptides supplies Thymosin Alpha-1 exclusively as a research-grade reagent for laboratory use and provides no dosing protocols, administration regimens, or therapeutic recommendations in any form.

Unopened lyophilized vials are stable under dry ambient conditions for short periods, but long-term storage should be at or below −20 °C, protected from light and moisture. Once reconstituted, keep the solution refrigerated at 2–8 °C and use within a few weeks; avoid repeated freeze–thaw cycles, which degrade peptide integrity. Bring vials to room temperature before opening to prevent condensation on the lyophilized cake.

Thymosin Alpha-1 belongs to the thymic peptide family and is frequently compared with related immunomodulatory compounds. It is mechanistically distinct from Thymosin Beta-4 (and its synthetic fragment TB-500), which is an actin-sequestering peptide studied for tissue repair rather than immune modulation, despite the shared "thymosin" naming. Within the immune-peptide space it is studied alongside compounds such as KPV, an anti-inflammatory tripeptide with a different mechanism. Researchers selecting a comparator should anchor design to the specific pathway of interest, because the thymosin peptides do not share a single mechanism.

A 10 mg vial of Thymosin Alpha-1 reconstituted with 2 mL of bacteriostatic water yields a final concentration of 5 mg/mL, or 5,000 mcg/mL. Other diluent volumes scale linearly: 1 mL gives 10 mg/mL, 5 mL gives 2 mg/mL.

Reconstitution procedure:

1. Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
2. Sanitise both rubber stoppers with an alcohol swab.
3. Pull the chosen diluent volume into a sterile transfer syringe.
4. Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and can denature peptide at the air–water interface.
5. Invert slowly or swirl gently until dissolved. Do not vortex or shake.
6. Refrigerate at 2–8 °C.

1. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert opinion on biological therapy. 2004. PMID 15102605.
2. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and hormones. 2016. PMID 27450734.
3. Romani L et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004. PMID 14982877.
4. Garaci E. Thymosin alpha1: a historical overview. Annals of the New York Academy of Sciences. 2007. PMID 17567941.